TCT 2020 | Using OCT to Detect Vulnerable Plaque even with Negative FFR

Optical coherence tomography (OCT) has proven useful in diabetic patients, even those with negative FFR. 

TCT OCT placas vulnerables incluso con FFR negativo

These findings make us rethink the ischemia and functional revascularization paradigm vs. the anatomical findings of vulnerable plaque. 

Diabetic patients with lesions that might be deferred base don FFR might benefit from OCT to find in these plaques certain risk features that will make them prone to developing events. 

This study called COMBINE OCT-FFR included 547 patients assessed with FFR and revascularized according to the standard cutoff value of 0.8. Patients with negative lesions (>0.8) were assessed with OCT and classified in vulnerable or not vulnerable according to fibroatheroma cap thickness. 


Read also: Further Evidence in Favor of Non-Invasive Vasospasm Diagnosis.


Primary end point was a composite of cardiac death, vessel related MI, clinically justified revascularization, or hospitalization for unstable or progressive angina. 

After 18-month followup, there was a 5-fold higher event rate in patients with vulnerable lesions due to thin-cap fibro-atheroma defined by OCT (13.3% vs 3.1%; HR 4.7).

There were no differences in events in patients undergoing revascularization based on FFR.


Read also: Diabetes Could Decide between Ticagrelor and Prasugrel.


According to Dr. Kedhi, this study has shown for the first time that diabetic patients might benefit from revascularization of certain lesions despite their not being functionally significative.

These conclusions have had different repercussion among panelists, which clearly shows controversy.

Original Title: Combined optical coherence tomography and fractional flow reserve assessment to better predict adverse event outcomes in DM patients.

Reference: Presentado por Kedhi E. en el TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....